Magungunan Blockbuster Don Duba Don Nan gaba

Clarivate Plc, kamfani na duniya don samar da bayanai da fahimta don haɓaka saurin ƙirƙira, a yau ya sanar da sakin rahotonsa na shekara-shekara na Drug to Watch™, gano magungunan da ke shiga kasuwa ko ƙaddamar da mahimman alamu a cikin 2022 waɗanda aka annabta don cimma matsayin blockbuster 2026. Leveraging Clarivate bayanai da kuma basira, manazarta gano bakwai marigayi-mataki gwajin jiyya cewa sun hasashen za su sadar da shekara-shekara tallace-tallace na fiye da $1 biliyan a cikin shekaru biyar. Wadannan jiyya sun ƙunshi sassa daban-daban na warkewa, daga yanayi kamar cutar Alzheimer (AD), asma da nau'in ciwon sukari na 2 (T2DM), waɗanda ke addabar dubun-dubatar marasa lafiya a duk duniya, zuwa cututtukan da ba kasafai ba, kamar transthyretin amyloidosis (ATTR) , da sauransu.

Rahoton ya kuma ba da bincike mai zurfi na mahimman alluran rigakafin COVID-19 da hanyoyin kwantar da hankali tare da mahimman wuraren haɓaka hanyoyin warkewa don kallo, kamar ƙwayoyin cuta da ƙwayoyin cuta, CRISPR, gano magungunan da ke haifar da hankali na wucin gadi da koyan injin, RNA da hanyoyin magance cutar kansa. . Bugu da kari, rahoton ya yi nazari kan magunguna da ilimin halittu da ke fuskantar gasa ta gaba daya saboda kariyar ikon Amurka a shekarar 2022.

Kewaya yanayin yanayin kiwon lafiya na duniya yana ƙara sarƙaƙƙiya, kuma gano, haɓakawa da kasuwanci na samun nasarar jiyya waɗanda ke canza rayuwar marasa lafiya na iya zama ƙalubale, musamman a lokutan da ba a taɓa samun irinsu ba a yau. Rahoton Drugs to Watch yana ba da haske game da jiyya na gwaji tare da babban alƙawari don tabbatar da ingantattun sakamakon haƙuri da ƙoƙarin ba da kuɗi na gaba na sabbin magunguna. Ta hanyar daidaitawa, haɓakawa da kuma hanyoyin samar da ɗimbin jama'a, kamfanonin da ke bayan waɗannan jiyya masu ban sha'awa suna haɓaka ɗimbin ɗimbin ɗimbin ƴan takarar jiyya - haɓaka ƙwarewa mai zurfi a cikin wuraren da suka dace da hanyoyin warkewa da dabarun dogon lokaci don neman hanyoyin warkewa don waɗannan yanayi.

Daga cikin sabbin magunguna da masana kimiyyar halittu wadanda ko dai sun sami amincewa ko kuma a shirye suke su yi, Clarivate ya gano wasu jiyya guda bakwai da ta yi imanin cewa za su iya cimma matsayi na blockbuster a cikin shekaru biyar masu zuwa. Magungunan 2022 don Kallon, sun haɗa da:

• Adagrasib, wanda Mirati Therapeutics Inc da Zai Lab Limited suka haɓaka - Wannan dogon jira, magani da aka yi niyya zai iya zama farkon irin wannan zaɓin jiyya a cikin marasa lafiya masu fama da cutar kansa (CRC) tare da maye gurbin KRASG12C, waɗanda a tarihi sun sami zaɓuɓɓukan magani kaɗan. Bambance-bambancen na yau da kullun na KRAS oncoprotein ana ɗaukarsu a al'adance makasudin magungunan da ba za a iya jurewa ba wanda ke sa hasashen shigarwar mai hana KRAS ga marasa lafiya da ke da ingantaccen ciwace-ciwacen ciwace-ciwace.

• Farimab, Roche da Chugai Pharmaceutical suka haɓaka - Ga marasa lafiya da ke fama da ciwon sukari macular edema (DME) ko rigar shekaru masu alaƙa da macular degeneration (AMD), faricimab yana ba da zaɓi mai yuwuwar mafi dacewa saboda za a gudanar da shi ƙasa akai-akai, a matsakaita, fiye da daidaitattun kulawa. . A matsayin farkon bispecific antibody da aka ƙaddamar a cikin ilimin ophthalmology, kuma yana da yuwuwar zama mafi inganci fiye da tsarin kulawa na yanzu, kodayake bayanai sun nuna ya zuwa yanzu ba ƙasa da ƙa'idar kulawa ba. Faricimab shine farkon mai hana VEGF/Ang-2 mai dual don kula da DME da rigar AMD (kuma farkon bispecific MAb a cikin yankin likitancin ido gabaɗaya).

• Lecanemab, Eisai Co Ltd da Biogen Inc suka haɓaka, kuma donanemab, daga Eli Lilly da Kamfanin - A cikin wannan kasuwar da ba a kula da ita, anti-Aβ MAbs lecanemab da donanemab suna shirye don bin diddigin alamar alamar FDA ta Amurka tana haɓaka amincewar ADUHELM don kula AD Lecanemab da donanemab na iya ba da bayanan bayanan asibiti daban-daban, waɗanda za a iya ƙarfafa su ta hanyar sakamako na 3 wanda ake sa ran za a bayar da rahoton farawa a ƙarshen 2022. Bayanai a cikin gwaje-gwaje na asibiti sun nuna cewa isassun bayanai ga mafi kyawun allurai na maganin anti-Aβ MAb zai iya zama tasiri a asibiti. farkon AD.

• Tsoro, Amgen da AstraZeneca suka haɓaka - Tezepelumab shine yiwuwar canza wasan ga marasa lafiya da marasa lafiya marasa TH2 ko TH2-ƙananan asma wanda fuka ba a sarrafa shi da kyau tare da corticosteroids inhaled, yanayin kulawa na yanzu. Idan an amince da shi, zai zama ilimin halitta-a-aji na farko ga wannan yawan majiyyaci. Tezepelumab zai yiwu ya zama masanin ilimin halitta na farko don tsananin TH2-ƙananan asma da kuma zaɓin magani ga marasa lafiya tare da TH2-high asma wanda hanyoyin kwantar da hankali ba su da nasara.

• Tirzepatide, wanda Eli Lilly da Kamfanin suka haɓaka - Tirzepatide yana ba da ragi mai jagorancin nuni a cikin asarar nauyi da haɓakawa a cikin sarrafa glycemic a cikin yawan masu haƙuri mai girma, wanda ke da yuwuwar rage haɗarin nau'in ciwon sukari na 2 (T2DM) da ke da alaƙa. Wani sabon magani wanda zai iya magance duka asarar nauyi da sarrafa glycemic fiye da jiyya na yanzu zai iya zama babban fa'ida ga sakamakon haƙuri.

• Vutrisiran, Alnylam Pharmaceuticals ya haɓaka - Don cututtukan ci gaba tare da buƙatu da yawa waɗanda ba a cika su ba, wannan magani yana kawo inganci, ingantaccen bayanin martabar aminci gabaɗaya, da haɓakawa a cikin bayarwa wanda zai amfanar ingancin rayuwa mai haƙuri. Wannan yawan masu haƙuri yana da ƴan zaɓuɓɓukan magani, musamman ga waɗanda ke da nau'in ATTR na daji. Ba wai kawai wannan magani ya shiga cikin kasuwar da ba a kula da shi gabaɗaya ba, yana da mafi dacewa dosing fiye da sauran takamaiman magungunan ATTR akan kasuwa.

Mike Ward, Shugaban Kimiyyar Rayuwa ta Duniya da Jagorancin Tunanin Kiwon Lafiya, Clarivate: "Yayin da kamfanonin harhada magunguna da fasahar kere-kere suka saka hannun jari mai yawa a cikin shekaru biyu da suka gabata don magance kalubalen da COVID-19 ya yi, sun kuma ci gaba da amfani da sabbin fasahohi don ƙirƙirar. magungunan da za su ba da zaɓuɓɓuka ga marasa lafiya masu fama da rashin ƙarfi ko a halin yanzu marasa magani waɗanda har yanzu suna wakiltar babban nauyin likita. Zaɓuɓɓukan da za a duba na magunguna na wannan shekara, da kuma zaɓin fasahar-da-kallo, sun nuna ƙaƙƙarfan kirkire-kirkire da ke cikin cibiyar harhada magunguna da fasahar kere-kere kuma za ta haifar da kyakkyawan sakamako ga marasa lafiya nan gaba.”

Duk da cutar ta COVID da ta tarwatsa masana'antar magunguna ta hanyoyi da yawa, daga rugujewar sarkar samar da kayayyaki da ke haifar da karancin manyan abubuwan da ke haifar da jinkirin gwaji na asibiti1, kamfanonin harhada magunguna da fasahar kere-kere suna ci gaba da haifar da manyan ci gaba a fannin likitanci. Masu yin ƙwayoyi suna samun babban ci gaba don buɗe fasahohin da za su sauƙaƙe magunguna na musamman. Masu gudanarwa suna nuna buɗaɗɗe ga sabbin fasahohi da dabaru da kuma ɗokin magance cututtuka waɗanda babu magani kaɗan ko babu. Koyaya, yana da mahimmanci ga kamfanoni su tabbatar da ƙimar su don samun amincewar kasuwa kuma sanya su isa ga marasa lafiya.